

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

1012825
PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

LITERATUUR KOPIEEN

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70 // (A61K 31/70, 31:17)	A2	(11) International Publication Number: WO 95/17899 (43) International Publication Date: 6 July 1995 (06.07.95)
(21) International Application Number: PCT/IB95/00153 (22) International Filing Date: 20 December 1994 (20.12.94) (30) Priority Data: 08/169,253 20 December 1993 (20.12.93) US (71) Applicants: COMPAGNIE DE DEVELOPPEMENT AGUET-TANT [FR/FR]; 1, rue Alexander-Fleming, F-69007 Lyon (FR). VILA, Jorge, R. [FR/FR]; 1, rue Alexander-Fleming, F-69007 Lyon (FR). (72) Inventor: MALLEY, Serge, D.; 1, rue Alexander-Fleming, F-69007 Lyon (FR). (74) Agent: CABINET GERMAIN & MAUREAU; 20, boulevard Eugène-Deruelle, Boîte postale 3011, F-69392 Lyon Cédex 03 (FR).		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MIXTURES OF DIDEOXY-NUCLEOSIDES AND HYDROXYCARBAMIDE FOR INHIBITING RETROVIRAL SPREAD (57) Abstract <p>A method and composition for inhibiting the spread of a retrovirus such as HIV of a human cell population in which the retrovirus such as HIV is present has been found. The spread of the retrovirus is inhibited by treatment of the cells with a synergistic combination mixture of a dideoxy-ribonucleoside excluding AZT and hydroxycarbamide.</p>		

SECRET

SECRET

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Mixtures of Dideoxy-Nucleosides and
Hydroxycarbamide for Inhibiting Retroviral Spread

5 FIELD OF THE INVENTION

The present invention relates to a combination of a reverse transcriptase inhibitor and hydroxycarbamide in a synergistically effective amount wherein the combination is useful
10 in inhibiting retroviral spread.

BACKGROUND OF THE INVENTION

The expression "Acquired Immuno-Deficiency Syndrome" (AIDS) was first used in 1981 to describe a state of
15 cellular immune deficiency in homosexuals, characterized by the appearance of opportunistic infections and Kaposi's Sarcoma evolving very aggressively (CDC (Center for Disease Control), MMWR, 30 : 305-308.DC, (1981)). In 1983 a
20 retrovirus since called HIV (Human Immunodeficiency Virus type 1) was isolated among AIDS patients (Barré-Sinoussi F. et al Science, 220 : 868-870 (1983)).

Over the past several years, researchers and
25 clinicians have gained considerable experience in studying and caring for individuals infected with HIV throughout the often prolonged course of HIV disease and AIDS. On the basis of this experience, it has become clear that the pathogenic mechanisms underlying
30 HIV infection and disease are not unidimensional, but rather are extremely complex (Fauci AS., Science, 239, 617, (1988)). Any attempt to design a comprehensive therapeutic strategy for HIV disease must take this fact into account. (Fauci, 1993, Science, 262:1011-
35 1018).

After entry of the HIV virus into cells and uncoating of the HIV particle, reverse transcription

- 2 -

of the viral RNA genome into DNA replicas occurs. Among several forms of unintegrated viral DNA (now containing the long repeats [LTRs], at both the 5' and the 3' ends), only the two-LTR linear forms can integrate into the host genome. Such a process appears strictly dependent upon cell activation/replication of T lymphocytes, although "resting" T cells are clearly susceptible to HIV infection. (Zack J.A. et al, *Cell*; 61, 213-222, (1990)). Furthermore, part of the reverse transcription process also can occur in unactivated T cells, a process that results in the accumulation of incomplete DNA molecules, which may persist for several hours and remain capable of being integrated into the host genome if the cell undergoes sufficient activation (Zack J.A. et al, *Cell* ; 61, 213-222, (1990)). Therefore, infected "resting" CD4⁺T lymphocytes can be considered a transient viral reservoir in infected individuals (Bokrinsky M.I. et al; *Science*, 254, 423-427, (1991)). These observations are of particular importance in anatomic compartments such as the peripheral blood and lymphoid organs, where the CD4⁺ T cell subset represents the predominant infected cell type (Schmittman S M. et al, *Science*, 245,305-308, (1989)); (Fox CH. et al *J. Infect Dis*; 164, 1051-1057, (1991)).

The above discussion provides a sound scientific basis for blocking the initial burst of virus replication and dissemination as well as the persistent replication throughout the course of disease by treating HIV-infected individuals with anti-retroviral agents from the earliest time that HIV infection is recognized through the entire course of infection. Unfortunately, currently available agents are only partially effective in suppressing virus

- 3 -

replication and spread, and this effect is transient (Hirsch MS, et al, *New Engl. J. Med.* 328 1686, (1993)). Clear cut, but limited, benefit is seen when 3'-azido-2',3'-dideoxythymidine or azidothymidine (AZT) is given to a patient with advanced HIV disease, and the benefits of early intervention are usually only temporary and do not result in significant long-term advantages with regard to the course of disease and death. (Fauci, 1993, *Science*, 262:1011-1018).

A number of 2'-3'-dideoxynucleosides have been found to be useful for the treatment or prophylaxis of retroviral infections and especially HIV and AIDS. Examples of such materials include: 2',3'-dideoxycytosine (ddC); 2',3'-dideoxy-adenosine (ddA); 2',3'-dideoxy-guanosine (ddG); and 2',3'-dideoxy-inosine (ddI) and 2',3' didexoxy-thymidine (ddT). See European patent application 0206497 and published PCT application number WO 87/01284.

Hydroxycarbamide (HC) was initially synthesized over 120 years ago and has been found to demonstrate activity against a broad spectrum of tumors. (Donehower, *Seminars in Oncology*, Vol. 19, No. 3, Suppl. 9 (June) 1992: pp 11-19). Additionally, hydroxycarbamide has been used as a viricide. In published PCT application number WO 93/09718, hydroxycarbamide is taught to be useful in a hydrogel polymer coating of a blood bag in order to inhibit viral and HIV infectivity.

Gao et al (*PNAS, USA*, Vol. 90, pp. 8925-8928, October 1993) disclose that hydroxyurea (hydroxycarbamide) treatment of peripheral blood lymphocytes (PBLs) decreases dNTP levels and the DNA synthesis rate to levels comparable to quiescent PBLs.

- 4 -

The article alleges a possible use of hydroxyurea in AIDS therapy.

However, there still remains a need for more effective treatments for the suppression of retroviruses and, in particular, the prevention and/or inhibition of HIV and viral spread. By viral spread, it is intended to include the inhibition of viral replication, and also may include the ability of inhibiting the virus to infect a further host cells.

Objectives of the present invention in the search for new antiretroviral agents include:

1) the identification of compounds with less toxicity and antiviral activity greater than AZT.

2) the development of drug combinations which provide an additive or synergistic effect and decrease the probability of drug resistant isolates.

BRIEF SUMMARY OF THE INVENTION

The present invention relates to a combination of a reverse transcriptase inhibitor and hydroxycarbamide in a synergistic combination wherein the synergistic combination is capable of preventing and/or inhibiting the spread of retroviruses including HIV. More specifically, the present invention relates to a method of preventing and/or inhibiting the spread of retroviruses, including HIV (HIV-1 and HIV-2), HTLV-1, HTLV-2, SIV or HSV, by exposing a cell population, including cells infected by a retrovirus such as, for example, HIV, to a synergistic combination of a reverse transcriptase inhibitor and hydroxycarbamide. Additionally, the present invention encompasses the treatment of HIV-infected and AIDS patients with a synergistic combination of a reverse transcriptase

- 5 -

inhibitor and hydroxycarbamide in order to prevent and/or inhibit the spread of HIV in these patients.

5 In a preferred embodiment of the present invention, the reverse transcriptase inhibitors include dideoxynucleosides, such as, for example, ddI, ddA, ddG and ddT (DT4).

10 In particular and in the preferred combination of the present invention, it has been found that a synergistic combination of hydroxycarbamide (HC) and 2',3'-dideoxy-inosine (ddI) can be formed which is especially effective in preventing and/or inhibiting HIV spread. The preferred embodiment of the invention encompasses a composition including a pharmaceutical composition comprising a synergistic combination of
15 ddI and HC. The pharmaceutical composition can optionally contain a pharmaceutically acceptable carrier and/or excipient and/or vehicle. The preferred method of the instant invention comprises preventing and/or inhibiting retroviral or HIV spread
20 by treating a cell population, including cells infected with HIV, with a synergistic combination of ddI and HC. Additionally, the preferred method comprises treating an HIV infected or AIDS patient with a synergistic combination of ddI and HC so as to
25 prevent and/or inhibit HIV spread in the patient.

BRIEF DESCRIPTION OF THE FIGURES

30 Figure 1 is a study of the anti-viral activity of a mixture of ddI and HC on non-activated CD4+ lymphocytes infected with the HIV virus.

Figure 2 is a study of the antiviral activity of a mixture of AZT and HC.

Figure 3 illustrates the inhibition of viral spread by the mixture of HC and ddI in pre-activated

- 6 -

peripheral blood mononuclear cells (PBMC) culture infected with the HIV virus.

DETAILED DESCRIPTION OF THE INVENTION

5 The following examples of specific embodiments of the present invention are offered for illustrative purposes only and are not limiting with respect to the scope of the disclosure or claim coverage.

10 Testing of the mixture of dideoxyinosine (ddI) and hydroxycarbamide (HC) on the spread of the HIV virus was conducted under two types of conditions:

15 a) CD4⁺ lymphocytes purified from PBMC, and infected with HIV virus without prior activation/proliferation of these cells by phytohemagglutinin (PHA) and interleukin-2 (IL-2).

 b) PBMC preactivated by PHA and IL-2, then infected with the HIV virus.

Example 1

20 The activity of the mixture of ddI and HC on non-activated CD4⁺ lymphocytes, infected with HIV virus was studied.

 Non-activated CD4⁺ cells were infected, then treated for 7 days by HC, ddI or the combination of the two, then activated by PHA and IL-2 (PHA-IL-2).

25 Cellular viability between 90% and 100% was observed during the first seven days after infection, both for the infected control and for the infected cells treated with the two drugs separately or in combination. Comparable proliferative cellular
30 response was observed in the presence of PHA-IL-2 for the first 3 days (days 7-9) both in the six virus infected groups and in the non-infected, non-treated donor CD-4⁺ cells. This proliferative response is associated with cytopathic effect in the infected

- 7 -

control group, and in the groups treated with HC alone at 0.05 and 0.15 mM: these groups had greater than 50% loss of viability compared to the uninfected control group; this effect is due to viral replication and is accompanied by large-scale production of p24-HIV in the culture supernatant seen at day 15 (86215 pg of p24/ml for the infected control, 75470 and 82005 for 0.05 and 0.15 mM HC treatment groups, respectively) see figure 1.

The cytopathic effect was observed later for the cells treated with 5 μ M ddI and reached substantially the same level of p24 production as the infected control 10 days later at day 25 (101080 pg p24/ml), see figure 1.

The mixture of HC at 0.05 mM with ddI at 5 μ M does not substantially change the viral replication profile as compared to ddI alone (84883 pg p24/ml at day 25), see figure 1.

By contrast, a surprising synergistic effect is observed with the combination 0.15 mM of HC and 5 μ M of ddI, where no residual viral production is detectable (< 1 pg p24/ml) at day 7 and day 25 despite cellular proliferation which is identical to the non-treated, non-infected control (>90% cell viability measured by MTT test).

Figure 1, in particular, shows a study of the activity of a mixture of ddI and HC on non-activated CD4⁺ lymphocytes infected with the HIV virus. The CD4⁺ lymphocytes were purified from PBMC with immunomagnetic beads (Dynabeads[®] M450). These cells were infected with the HIV-1 virus strain IIIB at a multiplicity of infection of 5 000 tissue culture infectious dose (TCID) per 10⁶ cells (241pg/ml p24 antigen equivalent of virus). After 2 hours of virus-

- 8 -

cell contact, the cells were washed twice and placed in the culture medium RPMI 1640 (supplemented with 10% fetal calf serum (FCS), 2mM glutamine, penicillin 100 IU/ml and Streptomycin 100 µg/ml) at a density of 1.3x10⁶ cells/ml. ddI was immediately added at a concentration of 5 µM and HC at concentrations of 0.05 mM and 0.15 mM. The drugs and culture medium were partially renewed (50%) on day 4, maintaining the same concentration of each. On day 7, in order to remove the drugs, the cells were washed twice and put back in culture in the presence of PHA at a concentration of 1 µg/ml and recombinant IL-2 at a concentration of 20 U/ml. This culture was maintained until day 25, with partial renewal (50%) of the medium twice a week. The number of viable cells was quantified by a tetrazolium-based colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels, R. et al *J. Virol. Methods*, 20, 309-321, (1988)), and activity is expressed as a percentage of the signal in the drug-free and virus-free control. Viral replication was quantified by measuring the HIV-1 p24 antigen by ELISA using the Dupont de Nemours kit.

Example 2

In order to determine whether or not this synergistic effect of ddI in a mixture with HC is specific to ddI, or whether a similar effect could be observed with AZT, a parallel study was conducted combining HC with azidothymidine (AZT) with surprising results.

As can be seen in figure 2, AZT alone at 5 µM has only slight antiviral activity, less than 1 log, (88.4%) inhibition (10030 pg p24/ml compared to 86215 pg p24/ml for infected control), less than ddI at the

- 9 -

same dose under the same conditions: 99.1% inhibition (766 pg p24/ml compared to 86215 pg p24/ml for infected control, see Figure 1). The drug concentrations used here are easily attainable in plasma (plasma concentration achievable under treatment conditions: 4 μ M for AZT and 10 μ M for ddI (Yarchoan et al , *New Engl. J. Med.* 321 726-738, (1989)).

Comparable proliferative cellular response was observed after stimulation by PHA-IL-2 in all groups. This proliferative response is associated with cytopathic effect in the infected control group, and in the groups treated with HC alone at doses of 0.05 and 0.15 mM and combined with AZT at 5 μ M (these groups had greater than 50% loss of viability compared to the uninfected control group). The combination of HC at 0.05mM and at 0.15 mM with AZT at 5 μ M (10108 and 9166 pg p24/ml, respectively) does not modify the viral replication profile compared to AZT alone (Figure 2).

The results show that the synergistic effect which eradicates HIV replication in CD4⁺ cells non-activated by PHA-IL-2 (Example 1) is not found from the mixture of HC with AZT.

In figure 2, there is shown a study of the activity of the combination of AZT and HC on non-activated CD4⁺ lymphocytes infected with the HIV virus. The CD4⁺ lymphocytes were purified from PBMC with immunomagnetic beads (Dynabeads[®] M450). These cells were infected with the HIV-1 virus strain IIIB at a multiplicity of infection of 5 000 tissue culture infectious dose (TCID) per 10⁶ cells (241pg/ml p24 antigen equivalent of virus). After 2 hours of virus-

- 10 -

cell contact, the cells were washed twice and placed in the culture medium RPMI 1640 (supplemented with 10% FCS, 2mM glutamine, penicillin 100 IU/ml and streptomycin 100 μ g/ml) at a density of 1.3×10^6 cells/ml. AZT was immediately added at a concentration of 5 μ M and HC at a concentration of 0.05 mM and 0.15 mM. The drugs and culture medium were partially renewed (50%) on day 4, maintaining the same concentration of each. On day 7, in order to remove the drugs, the cells were washed twice and put back in culture in the presence of PHA at a concentration of 1 μ g/ml and recombinant IL-2 at a concentration of 20 U/ml. This culture was maintained until day 25, with partial renewal (50%) of the medium twice a week. The number of viable cells was quantified by a tetrazolium-based colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels, R. et al *J. Virol. Methds*, 20,309-321, (1988)), and activity is expressed as a percentage of the signal in the drug-free and virus-free control. Viral replication was quantified by measuring the HIV-1 p24 antigen by ELISA using the Dupont de Nemours kit.

Example 3

A further study demonstrated inhibition of viral spread in preactivated PBMC culture infected with the HIV virus, by the mixture of HC and ddI.

PBMC preactivated with PHA and IL-2, were infected and treated by HC at 0.15 mM; this concentration corresponds to the IC_{50} (inhibitory concentration 50%) after 3 days measured by MTT test, with cellular viability >90% (this cell viability was determined by treating the cells with 2% Trypan Blue for 2 min and monitoring for dye exclusion). The combination of

- 11 -

0.15 mM of HC and 10 μ M of ddI does not modify the IC₅₀ and cellular viability.

As can be seen (figure 3), the virus replicated rapidly in the non-treated culture maintaining a stable level as from day 6 (day 6 = 71815; day 12 = 72750; day 20 = 62750 pg p24/ml). Treatment with ddI alone at 10 μ M and HC alone at 0.15 mM induces inhibition of 97.1% (2071 pg p24/ml) and 82.6% (12500 pg p24/ml) respectively at day 6. By contrast, a major synergistic effect is observed with the combination of 10 μ M ddI and 0.15 mM HC, with an inhibition of 99.8% (100 pg p24/ml) at day 6 and no residual viral production detectable (<1 pg. p24/ml) at day 12 and day 20.

This major synergistic effect, having been demonstrated with non-activated lymphocytes, where the combination of ddI with HC eradicates the HIV infection from the cells, is also observed here where lymphocytes are preactivated and treated with the combination of ddI and HC while the PBMC are replicating.

In figure 3, there is shown the elimination of viral replication by the combination of HC and ddI in preactivated PBMC culture infected with the HIV virus. The PBMC were purified from peripheral blood by discontinuous Ficoll density gradient centrifugation. The cells were grown at a density of 1.3×10^6 cells/ml in RPMI 1640 medium supplemented with 10% FCS, 2mM glutamine, penicillin 100 IU/ml and streptomycin 100 μ g/ml, in the presence of PHA at a concentration of 1 μ g/ml and recombinant IL-2 at 20 U/ml for 72 hours, then infected by HIV-1 strain IIIB at a multiplicity of 5000 TCID for 10^6 cells (241pg/ml p24 antigen equivalent of virus). In figure 3, the first time

- 12 -

point represents viral infection of the cells. After 2 hours of virus-cell contact, the cells were washed twice and placed in the culture medium containing IL-2 but without PHA in the presence of ddI at a concentration of 10 μ M and of HC at a concentration of 0.15 mM. These cultures were maintained for 20 days, with partial renewal of the medium and of the two drugs twice a week maintaining the initial concentration. At day 6 and day 14 fresh uninfected donor PBMC were added (5×10^5 /ml) to replenish aged cultures (*Nature*, 361:1993, 650-654). The number of viable cells was quantified by a tetrazolium-based colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels, R. et al *J. Virol. Methods*, 20:309-321, (1988)), and activity is expressed as a percentage of the signal in the drug-free and virus-free control. Viral replication was quantified by measuring the HIV-1 p24 antigen by ELISA using the Dupont de Nemours kit.

Gao et al in *Proc. Nat'l. Acad. Sci. USA*, cited supra, teach that "human immunodeficiency virus type 1 (HIV-1) viral DNA synthesis in quiescent and activated peripheral blood lymphocytes (PBLs) were studied. Incomplete viral DNA (previously demonstrated to be associated with HIV-1 virions) is carried by HIV-1 virions into quiescent and activated PBLs, contributing to the formation of an early viral DNA pool in these cells. The viral DNA is subsequently completed but only extremely slowly and inefficiently in quiescent PBLs compared to that in stimulated PBLs. We find that this correlates with significantly lower levels of dNTP substrates in quiescent compared to activated PBLs. At these low dNTP concentrations, HIV-1 reverse transcriptase acts

- 13 -

in a partially distributive manner. Increasing dNTP concentrations from the levels of quiescent PBLs to the levels of activated PBLs increases the processive action of the reverse transcriptase, which in turn stimulates rapid and efficient formation of full length DNA. Furthermore, hydroxyurea treatment of stimulated PBLs decreases the dNTP levels and the DNA synthesis rate to levels comparable to quiescent PBLs. Our data therefore indicate that low levels of dNTP may explain why HIV-1 DNA is synthesized slowly and efficiently in quiescent PBLs and suggest that pharmacologic induction of low dNTP levels represents a therapeutic approach for inhibition of HIV-1 replication."

The explanation by Gao et al given for slow and inefficient HIV-1 viral DNA synthesis in quiescent PBLs may well be valid, given that viral DNA is synthesized completely in PBLs under conditions of sufficient replication/activation (Fauci, 1993, *Science*, 262:1011-1018.).

However, Gao et al fail to explain how HC (hydroxycarbamide or hydroxyurea) by means of its inhibitory action on ribonucleotide reductase, and the reduction of dNTP pools in activated lymphocytes, would constitute a potential use of HC in the treatment of patients with AIDS. At the concentration of 1mM, HC partially reduces the various dNTP pools studied, see figure 4(a).

A comparison of figure 4(a), and table 1 (dNTP pools in quiescent and PHA stimulated PBLs) of Gao et al, shows that under the same conditions (PBLs infected with HIV-1 in the presence and the absence of PHA) the reduction of pool levels in table 1 is substantially

- 14 -

greater than the HC-induced reduction over an equivalent 48 hour period. (See table 1).

5 If one accepts what Gao et al hypothesize that viral DNA synthesis in "resting" cells while slow and inefficient eventually produces complete viral DNA capable of integration, it is difficult to understand how, under the conditions described, HC could have activity in AIDS patients. It is demonstrated in the present disclosure (figure 1) that quiescent cells in the presence of HC at nontoxic concentrations are incapable of preventing the production of infectious virions as measured by the HIV 1 p24 antigen in the supernatant after stimulation by PHA and IL-2.

10 An explanation of the HC-induced depletion of the dNTP pools which "significantly reduces the rate of HIV-1 DNA synthesis and inhibits the completion of viral DNA synthesis in PHA stimulated PBLs", see figure 4(b) of Gao et al, would be that HC at the concentration of 1mM is cytotoxic for non-activated lymphocytes pretreated for 24 hours and activated by PHA and IL-2 for the following 48 hours in the presence of HC. Under such conditions, greater than 70% of the PBLs die due to the drug's toxicity.

15 Under the heading "Potential use of hydroxyurea in AIDS therapy", Gao et al state that "by depleting the cellular dNTP pool, hydroxyurea is expected to increase the therapeutic effect of nucleoside analogs 3'-azido 3'-deoxythymidine, dideoxyinosine, or dideoxycytosine, which act as competitors of cellular dNTP". If this were true, one would expect that, in the treatment of infected "resting" cells where dNTP pools are found at their lowest levels, nucleoside analogs would have a major effect. However, as shown in the present disclosure, (figures 1 and 2) the

- 15 -

5 treatment of "resting" cells infected by HIV-1 for
seven days and treated by AZT alone at 5mM has only a
slight effect on viral replication as measured by p24
antigen. Similarly, for ddI alone, at the same
10 concentration, and under the same conditions, viral
replication is only temporarily and partially
inhibited, regaining the level of the infected control
at day 25 (figure 1). It is not, therefore, in
accepting the Gao et al explanation that one could
15 have predicted an increase in the therapeutic effect
in AIDS therapy by associating a nucleoside analog
with HC, all the more so since the results in the
present disclosure show that a surprising synergistic
effect is observed for the association of HC and ddI,
but not at all for HC and AZT.

The subject of the present invention is also a new
composition for the treatment of a cell population in
the presence of a retrovirus. Additionally, the
invention includes a pharmaceutical composition
20 intended, in particular, for the treatment and
prevention of retroviral infections, especially those
linked to HIV and AIDS wherein the composition
contains a synergistic combination of hydroxycarbamide
(HC) and a reverse transcriptase inhibitor, in
25 particular a synergistic combination of a dideoxy-
nucleoside except AZT and hydroxycarbamide, most
preferably a synergistic combination of dideoxyinosine
and hydroxycarbamide as active principle, in a
pharmaceutically acceptable vehicle. The composition
30 of the invention can also contain inert or
pharmacodynamically active additives, carriers and/or
excipients.

The pharmaceutical composition of the invention can
take the form of a lyophilized powder of the active

- 16 -

5 substance, to be dissolved immediately before use in a physiological solution for the purpose of injection. The medicament can then be administered parenterally, for example intravenously, intraperitoneally, in the cerebrospinal fluid, and the like. For injection, the active principle is dissolved in a physiological solution until the desired concentration for administration is obtained.

10 The pharmaceutical composition according to the invention can also take a form which is suitable for oral administration. For example, suitable forms are tablets, hard gelatin capsules, dragées, powders and granules. The formation of such oral forms is well-known to those skilled in the art. Any of the known formulations are useful in preparing the instant oral pharmaceutical compositions.

15 As regards the dosage of the medicament according to the invention, it will be clear to the artisan that the doses to be administered are variable according to the treatment period, and frequency of administration, the host and the nature and severity of the disease and that the dosages can be easily determined without any undue amount of experimentation.

20 The compositions of the invention are administered in substantially non-toxic dosage concentrations sufficient to insure the release of a sufficient dosage unit of the present synergistic combination into the patient to provide the desired inhibition of the spread of the retrovirus. The actual dosage administered will be determined by physical and physiological factors such as age, body weight, severity of condition, and/or clinical history of the patient. With these considerations in mind, the dosage of the instant synergistic combination for a

- 17 -

particular subject can be readily determined by the physician. It might be noted that in extreme cases a dosage approaching the toxic level may be the acceptable treatment protocol.

5 For example, in the treatment of HIV-infected and AIDS patients, the composition can comprise from about 1 to 66 mg/Kg/day of ddI and from about greater than 5 mg/Kg/day to about 20 mg/Kg/day of HC.

10 The invention also covers the use of hydroxycarbamide (HC) and dideoxyinosine in combination with other medicinal compositions intended for the treatment of retroviral infections and tumors. Immunostimulants and immunomodulators such as for example cytokines, including IL-2, IL-12 and
15 interferon molecules can be used in combination with the present invention.

A preferred range for in vitro administration of the compositions of the present invention includes hydroxycarbamide in a concentration greater than 0.05
20 mM and less than or equal to 0.25mM in combination with a dideoxynucleoside except AZT such as ddI at concentrations which are generally known and used in the art. A preferred embodiment of the present invention utilizes HC at 0.15 mM and the
25 dideoxynucleoside such as ddI in a range of between about 0.01 μ M to about 100 μ M, preferably between about 2.5 μ M to about 25 μ M, most preferably from about 5 μ M to about 10 μ M.

30 All of the references cited hereinabove are expressly incorporated herein, in toto, by reference thereto.

The invention has been described with reference to specific and preferred embodiments. It will be recognized by those skilled in the art that numerous

- 18 -

changes and substitutions may be made without departing from the spirit and scope of the invention.

- 19 -

We Claim:

1. A composition useful for inhibiting the spread of a retrovirus in a cell population comprising a mixture of at least one dideoxynucleoside excluding AZT and hydroxycarbamide wherein the hydroxycarbamide is present in a synergistically effective amount with respect to the amount of the dideoxynucleoside.

2. A composition according to claim 1, wherein the dideoxynucleoside is at least one of ddI, ddA, ddG or ddT.

3. A composition according to claim 2, wherein the dideoxynucleoside is ddI.

4. A composition according to any one of claims 1, 2 or 3, wherein the retrovirus is HIV.

5. A composition according to any one of claims 1, 2 or 3, wherein the retrovirus is HIV-1.

6. A composition according to claims 1, 2 or 3, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $.01\mu\text{M}$ to $100\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25 mM .

7. A composition according to claim 6, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $2.5\mu\text{M}$ to $25\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25 mM .

8. A composition according to claim 6, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $5\mu\text{M}$ to $10\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25 mM .

- 20 -

5 9. A composition according to claim 1, 2 or 3, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $5\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM .

10 10. A composition according to claim 4, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $5\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM .

15 11. A composition according to claims 1, 2 or 3, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $10\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM .

20 12. A composition according to claim 4, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $10\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM .

25 13. A composition according to claim 4, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $0.01\mu\text{M}$ to $100\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25mM .

30 14. A composition according to claim 13, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $2.5\mu\text{M}$ to $25\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25mM .

15. A composition according to claim 13, wherein the amount of dideoxynucleoside is such as to provide

- 21 -

a concentration of about $5\mu\text{M}$ to $10\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25 mM .

5 16. A method of inhibiting spread of a retrovirus in a human cell population in the presence of the retrovirus comprising administering to the human cell population an effective spreading inhibiting amount of a composition according to claim 1.

10 17. A method according to claim 16, wherein the dideoxynucleoside comprises at least one of ddI, ddA, ddG or ddT.

18. A method according to claim 17, wherein the dideoxynucleoside is ddI.

15 19. A method according to any one of the claims 16, 17 or 18, wherein the retrovirus is HIV.

20. A method according to claim 19, wherein the retrovirus is HIV-1.

20 21. A method according to any one of the claims 16, 17 or 18, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $0.01\mu\text{M}$ to $100\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25mM .

25 22. A method according to claim 19, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $0.01\mu\text{M}$ to $100\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25mM .

30 23. A method according to claims 21 or 22, wherein the amount of dideoxynucleoside is such as to provide a concentration of about $2.5\mu\text{M}$ to $25\mu\text{M}$ and the amount of the hydroxycarbamide is such as to provide a

- 22 -

concentration greater than 0.05mM and equal to or less than about 0.25mM.

5 24. A method according to claim 21, wherein the amount of dideoxynucleoside is such as to provide a concentration of about 5 μ M to 10 μ M and the amount of the hydroxycarbamide is such as to provide a concentration greater than 0.05mM and equal to or less than about 0.25mM.

10 25. A method according to any one of the claims 16, 17 or 18, wherein the amount of dideoxynucleoside is such as to provide a concentration of about 5 μ M to 10 μ M and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM.

15 26. A method according to claim 19, wherein the amount of dideoxynucleoside is such as to provide a concentration of about 5 μ M and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM.

20 27. A method according to any one of the claims 16, 17, or 18, wherein the amount of dideoxynucleoside is such as to provide a concentration of about 10 μ M and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM.

25 28. A method according to claim 19, wherein the amount of dideoxynucleoside is such as to provide a concentration of about 10 μ M and the amount of the hydroxycarbamide is such as to provide a concentration of about 0.15mM.

**CORRECTED
VERSION***

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/70 // (A61K 31/70, 31:17)	A3	(11) International Publication Number: WO 95/17899 (43) International Publication Date: 6 July 1995 (06.07.95)
(21) International Application Number: PCT/IB95/00153 (22) International Filing Date: 20 December 1994 (20.12.94) (30) Priority Data: 08/169,253 20 December 1993 (20.12.93) US (71) Applicants: COMPAGNIE DE DEVELOPPEMENT AGUET- TANT [FR/FR]; 1, rue Alexander-Fleming, F-69007 Lyon (FR). VILA. (72) Inventor: MALLEY, Serge, D.; 1, rue Alexander-Fleming, F-69007, Lyon (FR). VILA, Jorge, R.; 1, rue Alexander-Fleming, F-69007 Lyon (FR). (74) Agent: CABINET GERMAIN & MAURÉAU; 20, boulevard Eugène-Deruelle, Boîte postale 3011, F-69392 Lyon Cédex 03 (FR).	(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 10 August 1995 (10.08.95)	
(54) Title: MIXTURES OF DIDEOXY-NUCLEOSIDES AND HYDROXYCARBAMIDE FOR INHIBITING RETROVIRAL SPREAD		
(57) Abstract A method and composition for inhibiting the spread of a retrovirus such as HIV of a human cell population in which the retrovirus such as HIV is present has been found. The spread of the retrovirus is inhibited by treatment of the cells with a synergistic combination mixture of a dideoxy-ribonucleoside excluding AZT and hydroxycarbamide.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				